Kenneth Hoellein
Internal Medicine · Philadelphia, PANPI 1720047277
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,000 of the $18,130 with a category attached, or 66.2%. 28 manufacturers reported payments, led by AstraZeneca at 55.2% of the total. Reporting peaked in 2021 at $8,123 and has fallen 97.4% since, to $212 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $69.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$10K
- Lilly USA, LLC$5K
- Novo Nordisk$984
- Daiichi Sankyo Inc.$415
- Pfizer$331
- GSK$217
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$12,00066%
- Travel & lodging$540%
- Food & beverage$5,35630%
- Education$6614%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $10,009 |
| Lilly USA, LLC | 19 | $4,809 |
| Novo Nordisk | 50 | $984 |
| Daiichi Sankyo Inc. | 18 | $415 |
| Pfizer | 34 | $331 |
| GSK | 15 | $217 |
| Esperion Therapeutics, Inc. | 4 | $188 |
| Astellas Pharma US Inc | 11 | $171 |
| Global Blood Therapeutics, Inc. | 8 | $122 |
| Teva Pharmaceuticals USA, Inc. | 5 | $86 |
| Johnson & Johnson | 4 | $85 |
| BD | 3 | $85 |
| Boehringer Ingelheim | 4 | $84 |
| Merck | 5 | $81 |
| Mannkind Corporation | 2 | $78 |
| AbbVie(2 entities) | 4 | $69 |
| Gilead | 3 | $47 |
| Arbor Pharmaceuticals, Inc. | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Akebia Therapeutics Inc | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,130 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.